Abstract
The National Institute for Health and Care Excellence (NICE) has given draft approval to the migraine prophylaxis infusion eptinezumab (Vyepti; Lundbeck), as a treatment option for people who have at least four migraine days per month and have had no relief from three oral preventive drugs. Eptinezumab, a calcitonin gene-related peptide (CGRP) inhibitor, is administered […]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
